Core EQ Innovator™ Vaccine Recognized as Best New Product for Companion Animals | 2018
Zoetis received top honors in the Best New Product - Companion Animals category for Core EQ Innovator™ vaccine for horses in the 2018 Animal Pharm Awards competition. The vaccine exemplifies Zoetis leadership in research and development, bringing customers innovative solutions to their evolving and most pressing healthcare challenges.
Core EQ Innovator™ vaccine is the first and only equine vaccine to protect against all five core equine diseases – West Nile virus, Eastern and Western Equine encephalomyelitis, tetanus and rabies – in one vaccine. These diseases are designated as “core” by the American Association of Equine Practitioners because all horses are at risk for exposure, all have a high fatality rate, and some may present a potential human health risk.
Vaccinating against all core diseases is an established and acknowledged standard of veterinary care. Until the advent of Core EQ Innovator, separate injections against each of the five core diseases was required. As a result, fewer than one in seven horses have been protected against all core diseases. Core EQ Innovator makes it easier than ever to provide complete core protection to every horse, every spring with a single injection.
In announcing the honor, Animal Pharm stated, “This year's winner was a product that brought much-needed innovation to the equine health space. In August 2018, Zoetis launched the Core EQ Innovator vaccine in the U.S. It became the first and only equine vaccine to protect against all five core equine diseases – West Nile virus (WNV), Eastern and Western equine encephalomyelitis, tetanus and rabies – in one product.
Animal Pharm's annual industry awards honor achievements within the animal health sector over the calendar year. Subscribers can nominate companies, products and employees in 12 award categories. A panel of judges comprised of industry experts evaluate the nominations and select the winners.